application

KuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA OperationsKuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA Operations

KuCoin EU Files MiCAR Application in Austria to Ensure Compliant EEA Operations

Key Takeaways: KuCoin EU Exchange GmbH ("KuCoin EU") is applying for a Markets in Crypto-Assets Regulation ("MiCAR") license in Austria…

3 weeks ago
VCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case AccuracyVCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case Accuracy

VCTI Launches BEAD Application Service to Help Broadband Providers Secure Funding Faster with Higher Business Case Accuracy

BEAD Resource Center Launches on VCTI Website SOMERSET, N.J., Feb. 5, 2025 /PRNewswire/ -- VCTI, the broadband expansion and network…

1 month ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

2 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

2 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement…

2 months ago
Adam Ferrari Health Science Scholarship Application Window ClosesAdam Ferrari Health Science Scholarship Application Window Closes

Adam Ferrari Health Science Scholarship Application Window Closes

January 10, 2025 10:30 ET  | Source: The Ferrari Foundation DENVER, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The application period…

2 months ago
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastomaNorgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing…

2 months ago
Alaskas Department of Revenue Forms Strategic Partnership with Saige Consulting to Overhaul the Permanent Fund Dividend Application SystemAlaskas Department of Revenue Forms Strategic Partnership with Saige Consulting to Overhaul the Permanent Fund Dividend Application System

Alaskas Department of Revenue Forms Strategic Partnership with Saige Consulting to Overhaul the Permanent Fund Dividend Application System

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The State of Alaska, Department of Revenue (DOR), in collaboration with Saige…

3 months ago
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic GalactosemiaApplied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

November 27, 2024 16:10 ET | Source: Applied Therapeutics NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.…

4 months ago
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic CancerAnocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer

Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer

November 26, 2024 03:00 ET | Source: Anocca AB Application to the European Medicines Agency (EMA) covers ANOC-001 as the…

4 months ago